Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Umbilical cord-derived allogeneic mesenchymal stem cell therapy - Vitro Biopharma

X
Drug Profile

Umbilical cord-derived allogeneic mesenchymal stem cell therapy - Vitro Biopharma

Alternative Names: AlloRx; AlloRx stem cells®

Latest Information Update: 01 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vitro Diagnostics
  • Developer The Foundation for Orthopaedics and Regenerative Medicine; Vitro Diagnostics
  • Class Mesenchymal stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pitt-Hopkins syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Osteoarthritis
  • Phase I/II COVID 2019 infections; Crohn's disease; Meniscus disorders; Pitt-Hopkins syndrome; Systemic lupus erythematosus
  • Phase I Amyotrophic lateral sclerosis; Angina pectoris; Autistic disorder; Cerebral palsy; Diabetes mellitus; Erectile dysfunction; Heart failure; Inflammatory bowel diseases; Interstitial cystitis; Multiple sclerosis; Osteoporosis; Parkinson's disease; Peripheral nervous system diseases; Peyronie's disease; Rheumatoid arthritis; Systemic scleroderma; Trigeminal neuralgia
  • Preclinical Alzheimer's disease; Stroke; Traumatic brain injuries

Most Recent Events

  • 27 Oct 2022 Phase-I clinical trials in Osteoarthritis (In children, In adults, In the elderly) in Antigua and Barbuda (Intra-articular) (NCT05147675)
  • 27 Oct 2022 Phase-I clinical trials in Osteoarthritis (In children, In adults, In the elderly) in Antigua and Barbuda (IV) (NCT05147675)
  • 07 Jan 2022 Phase-I clinical trials in Autistic disorder (In children, In adults, In the elderly) in USA (IV) (NCT05003960)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top